Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death.
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables.
Characterization of the influence of mediator complex in HIV-1 transcription.
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.
p21 regulates the HIV-1 restriction factor SAMHD1.
Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressure.
Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.